

Dept. Klinische Forschung Clinical Trial Unit

The role of patient organisations

Efficiency Strategies for Clinical Studies; April 28-30, 2015



Content

- Introduction
- Nature of "patient organisations" in Switzerland
- Patient's perspective
- Federal act on research involving human beeings;
 Jan. 2014
- Starting the process of patient involvement in Switzerland?
- Concluding discussion

Some personal information

- Born with a rare disease
- Characterized as a chronic condition
- Irregular acute episodes
- Health problems in childhood
- "New" health problems by getting older
- Three decades of very few bone-related problems
- Trained as an MD with an MPH





Patient and consumer organisations in Switzerland

- Umbrella organisations of affected people
- Disease related patient organisations and support groups
- Supporting- and councelling organisations
- Ombuds centres for patients

PRORARIS



Alliance Maladies Rares - Suisse Allianz Seltener Krankheiten - Schweiz Alleanza Malattie Rare - Svizzera





Association pour l'Information et la Recherche sur les maladies rénales Génétiques









BLACKSWAN®







Schrose tubéreuse de Bourneville. Tuberöse Sklerose Kornolex Sclerosi triberasa complessa

> Life state Analys, on line state cour. and force symposine /









Schweizerische Gesellschaft für Cystische Fibros Société Suisse pour la Mucoviscidose (CFCH) Società Svizzera per la Fibrosi Cistica (CFCH)





















PRORARIS

















Associantar Svicre Niemann Pick Swiss Niemann Pick Association






















Knochenmarktransplantation















Rare Disease Day, February 2015




Definitions (patients perspective)

- Clinical trial: a research project which aims to evaluate the effects of an intervention in connection with health
 - -> clinical research ≠ clinical care

- Role of the person in charge of care: individual care of the patient by respecting his needs
- Role of researcher: to gain knowledge which can be disseminated.
 The interests of the patient are not always identical

Céline Moret, representative of a patient organisation

Partners in a clinical trial



Benefits

No guarantee; the study is aimed at evaluating this topic

To consider

- Study phase
- Study methodology (placebo)
- Existing data
- Discussion with other participants

Céline Moret, representative of a patient organisation



Risks

Some unexpected events can happen:

- in relation to the intervention
- in relation to the tests during the clinical study

To take into consideration:



A clinical study has to evaluate the safety of a therapeutical intervention. Not all risks can be eliminated.



Federal Act on Research involving Human Beings (Human Research Act, HRA)

Art. 16 Informed consent

- 1 Persons may only be involved in a research project if they have given their informed consent. Consent must be given in writing; the Federal Council may specify exemptions.
- 2 The persons concerned must receive comprehensible oral and written information on:
 - the nature, purpose and duration of, and procedure for, the research project;
 - the foreseeable risks and burdens;
 - the expected benefits of the research project, in particular for themselves or for other people;
 - the measures taken to protect the personal data collected;
 - their rights.

Federal Act on Research involving Human Beings (Human Research Act, HRA)

Art. 19 Liability

- 1 Any person who carries out a research project involving persons shall be liable for damage suffered by them in connection with the project. The Federal Council may specify exemptions from liability.
- 2 Compensation claims become time-barred three years after the injured party has become aware of the damage and of the liable party, but no later than ten years after the completion of the research project. The Federal Council may specify a longer limitation period for particular research areas.
- 3 The provisions of the Code of Obligations4 on tort are otherwise applicable; in the exercise of official duties, the Government Liability Act of 14 March 19585, or cantonal government liability law, is applicable.

SCTO Forum Clinical Research 2015: General consent – Yes but how?

"Patients often have a huge interest in clinical research as they know first hand how life changes with a specific diagnosis. They need cures and hence, the majority of them has a positive attitude towards research. However patients want to become addressed and involved."

Karin Holm; representative of a patient organisation

Some key elements, EU countries

- Kees Bob (April 2012): Exchanging knowledge on participation of health consumers and patients in research, quality and policy. The Netherlands Organisation for Health Research and Development.
- Thematic website for best practices: www.patientpartner-europe.eu
- European Aids Treatment Group: Designing research protocols in collaboration with industry. Established relation with regulatory bodies
- Patient Partner (Dutch Genetic Alliance, EFGCP)
- Value+, Respect (EPF)
- EUROVISIONNET (Retina Suisse)

Patient Involvement in Clinical Research

A guide for Sponsors and Investigators



PATIENT INVOLVEMENT IN CLINICAL RESEARCH

A guide for Sponsors and Investigators





Patient involvement: becoming an active partner in research

- Research subject
- Information provider
- Advisor
- Reviewer
- Co-Researcher
- Driving Force

Patient involvement: professional perspective

- Representativeness
- Quality
- Bias
- Influence
- Consumer expectations,
- Cost increase and research duration
- Roles overlapping.
- Consumer involvement in health research: a review and research agenda; Jonathan Boote*, et. Al. 2002

Concluding discussion

- Is the Swiss health system ready for active patient involvement?
- Can Swiss patient organisations become active partners in research?
- Patient organisations as active partners: what do we need to lobby for or to do to get there?

• What is your experience in involving patient partner organisations in your research projects?

Thank you for your attention

Therese Stutz Steiger, MD MPH

Public health consultant

ProRaris: Board member

Tel: +41 31 931 07 76 Mobil: +41 79 626 16 57

stutzsteiger@bluewin.ch

Special thanks

Céline Moret, Retina Suisse